EGFR and squamous cell carcinoma: In addition, EGFR-mutated squamous cell carcinoma patients had significantly worse DFS and OS compared to EGFR wild-type squamous cell carcinoma patients (15.0 versus 44.6 months, log-rank χ2 =3.839, P = 0.050 for DFS; 30.1 versus 52.9 months, log-rank χ2 = 7.870, P = 0.005 for OS).